FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway

Sumin Kang, Shaozhong Dong, Ting Lei Gu, Ailan Guo, Michael S. Cohen, Sagar Lonial, Hanna Jean Khoury, Doriano Fabbro, D. Gary Gilliland, Peter Leif Bergsagel, Jack Taunton, Roberto D. Polakiewicz, Jing Chen

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

To better understand the signaling properties of oncogenic FGFR3, we performed phospho-proteomics studies to identify potential downstream signaling effectors that are tyrosine phosphorylated in hematopoietic cells expressing constitutively activated leukemogenic FGFR3 mutants. We found that FGFR3 directly tyrosine phosphorylates the serine/threonine kinase p90RSK2 at Y529, which consequently regulates RSK2 activation by facilitating inactive ERK binding to RSK2 that is required for ERK-dependent phosphorylation and activation of RSK2. Moreover, inhibition of RSK2 by siRNA or a specific RSK inhibitor fmk effectively induced apoptosis in FGFR3-expressing human t(4;14)-positive myeloma cells. Our findings suggest that FGFR3 mediates hematopoietic transformation by activating RSK2 in a two-step fashion, promoting both the ERK-RSK2 interaction and subsequent phosphorylation of RSK2 by ERK.

Original languageEnglish (US)
Pages (from-to)201-214
Number of pages14
JournalCancer Cell
Volume12
Issue number3
DOIs
StatePublished - Sep 11 2007

Fingerprint

MAP Kinase Signaling System
Tyrosine
Phosphorylation
Protein-Serine-Threonine Kinases
Proteomics
Small Interfering RNA
Apoptosis

Keywords

  • CELLCYCLE
  • SIGNALING

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway. / Kang, Sumin; Dong, Shaozhong; Gu, Ting Lei; Guo, Ailan; Cohen, Michael S.; Lonial, Sagar; Khoury, Hanna Jean; Fabbro, Doriano; Gilliland, D. Gary; Bergsagel, Peter Leif; Taunton, Jack; Polakiewicz, Roberto D.; Chen, Jing.

In: Cancer Cell, Vol. 12, No. 3, 11.09.2007, p. 201-214.

Research output: Contribution to journalArticle

Kang, S, Dong, S, Gu, TL, Guo, A, Cohen, MS, Lonial, S, Khoury, HJ, Fabbro, D, Gilliland, DG, Bergsagel, PL, Taunton, J, Polakiewicz, RD & Chen, J 2007, 'FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway', Cancer Cell, vol. 12, no. 3, pp. 201-214. https://doi.org/10.1016/j.ccr.2007.08.003
Kang, Sumin ; Dong, Shaozhong ; Gu, Ting Lei ; Guo, Ailan ; Cohen, Michael S. ; Lonial, Sagar ; Khoury, Hanna Jean ; Fabbro, Doriano ; Gilliland, D. Gary ; Bergsagel, Peter Leif ; Taunton, Jack ; Polakiewicz, Roberto D. ; Chen, Jing. / FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway. In: Cancer Cell. 2007 ; Vol. 12, No. 3. pp. 201-214.
@article{9dd259aa78744022a684260694b7c4ce,
title = "FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway",
abstract = "To better understand the signaling properties of oncogenic FGFR3, we performed phospho-proteomics studies to identify potential downstream signaling effectors that are tyrosine phosphorylated in hematopoietic cells expressing constitutively activated leukemogenic FGFR3 mutants. We found that FGFR3 directly tyrosine phosphorylates the serine/threonine kinase p90RSK2 at Y529, which consequently regulates RSK2 activation by facilitating inactive ERK binding to RSK2 that is required for ERK-dependent phosphorylation and activation of RSK2. Moreover, inhibition of RSK2 by siRNA or a specific RSK inhibitor fmk effectively induced apoptosis in FGFR3-expressing human t(4;14)-positive myeloma cells. Our findings suggest that FGFR3 mediates hematopoietic transformation by activating RSK2 in a two-step fashion, promoting both the ERK-RSK2 interaction and subsequent phosphorylation of RSK2 by ERK.",
keywords = "CELLCYCLE, SIGNALING",
author = "Sumin Kang and Shaozhong Dong and Gu, {Ting Lei} and Ailan Guo and Cohen, {Michael S.} and Sagar Lonial and Khoury, {Hanna Jean} and Doriano Fabbro and Gilliland, {D. Gary} and Bergsagel, {Peter Leif} and Jack Taunton and Polakiewicz, {Roberto D.} and Jing Chen",
year = "2007",
month = "9",
day = "11",
doi = "10.1016/j.ccr.2007.08.003",
language = "English (US)",
volume = "12",
pages = "201--214",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway

AU - Kang, Sumin

AU - Dong, Shaozhong

AU - Gu, Ting Lei

AU - Guo, Ailan

AU - Cohen, Michael S.

AU - Lonial, Sagar

AU - Khoury, Hanna Jean

AU - Fabbro, Doriano

AU - Gilliland, D. Gary

AU - Bergsagel, Peter Leif

AU - Taunton, Jack

AU - Polakiewicz, Roberto D.

AU - Chen, Jing

PY - 2007/9/11

Y1 - 2007/9/11

N2 - To better understand the signaling properties of oncogenic FGFR3, we performed phospho-proteomics studies to identify potential downstream signaling effectors that are tyrosine phosphorylated in hematopoietic cells expressing constitutively activated leukemogenic FGFR3 mutants. We found that FGFR3 directly tyrosine phosphorylates the serine/threonine kinase p90RSK2 at Y529, which consequently regulates RSK2 activation by facilitating inactive ERK binding to RSK2 that is required for ERK-dependent phosphorylation and activation of RSK2. Moreover, inhibition of RSK2 by siRNA or a specific RSK inhibitor fmk effectively induced apoptosis in FGFR3-expressing human t(4;14)-positive myeloma cells. Our findings suggest that FGFR3 mediates hematopoietic transformation by activating RSK2 in a two-step fashion, promoting both the ERK-RSK2 interaction and subsequent phosphorylation of RSK2 by ERK.

AB - To better understand the signaling properties of oncogenic FGFR3, we performed phospho-proteomics studies to identify potential downstream signaling effectors that are tyrosine phosphorylated in hematopoietic cells expressing constitutively activated leukemogenic FGFR3 mutants. We found that FGFR3 directly tyrosine phosphorylates the serine/threonine kinase p90RSK2 at Y529, which consequently regulates RSK2 activation by facilitating inactive ERK binding to RSK2 that is required for ERK-dependent phosphorylation and activation of RSK2. Moreover, inhibition of RSK2 by siRNA or a specific RSK inhibitor fmk effectively induced apoptosis in FGFR3-expressing human t(4;14)-positive myeloma cells. Our findings suggest that FGFR3 mediates hematopoietic transformation by activating RSK2 in a two-step fashion, promoting both the ERK-RSK2 interaction and subsequent phosphorylation of RSK2 by ERK.

KW - CELLCYCLE

KW - SIGNALING

UR - http://www.scopus.com/inward/record.url?scp=34548253333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548253333&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2007.08.003

DO - 10.1016/j.ccr.2007.08.003

M3 - Article

VL - 12

SP - 201

EP - 214

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 3

ER -